Edwards Lifesciences Corp EW.N, EW is expected to show a rise in quarterly revenue when it reports results on October 30 for the period ending September 30 2025
The Irvine California-based company is expected to report a 10.4% increase in revenue to $1.495 billion from $1.35 billion a year ago, according to the mean estimate from 29 analysts, based on LSEG data.The company's guidance on July 24 2025, for the period ended September 30, was for revenue between $1.46 billion and $1.54 billion.
LSEG's mean analyst estimate for Edwards Lifesciences Corp is for earnings of 59 cents per share. The company's EPS guidance on July 24 2025, for the period ended September 30, was between $0.54 and $0.60
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 14 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Edwards Lifesciences Corp is $88.00, about 6.6% above its last closing price of $82.19
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | 0.63 | 0.62 | 0.67 | Beat | 7.5 |
Mar. 31 2025 | 0.60 | 0.60 | 0.64 | Beat | 7.2 |
Dec. 31 2024 | 0.55 | 0.55 | 0.59 | Beat | 6.5 |
Sep. 30 2024 | 0.63 | 0.64 | 0.67 | Beat | 4.6 |
Jun. 30 2024 | 0.70 | 0.69 | 0.70 | Beat | 0.9 |
Mar. 31 2024 | 0.64 | 0.64 | 0.66 | Beat | 2.7 |
Dec. 31 2023 | 0.64 | 0.64 | 0.64 | Met | 0.4 |
Sep. 30 2023 | 0.59 | 0.59 | 0.59 | Met | -0.4 |
This summary was machine generated October 28 at 21:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)